^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Elrexfio (elranatamab-bcmm)

    i
    Other names: PF-06863135, PF 06863135, PF06863135, PF‑3135, PF3135, RN 613, RN613, RN-613
    Company:
    Pfizer
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    5d
    Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study. (PubMed, Transplant Cell Ther)
    IEC-HS is a rare but potentially fatal complication. Our disproportionality analysis identifies significant reporting signals for tisa-cel and cilta-cel. The high absolute number of cases observed for products like axi-cel appears to reflect high utilization rather than a disproportionate risk, underscoring the necessity of using statistical signal detection methods when interpreting spontaneous reports.
    Journal • Adverse events
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • Epkinly (epcoritamab-bysp) • Elrexfio (elranatamab-bcmm) • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel) • Lunsumio (mosunetuzumab-axgb) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • Columvi (glofitamab-gxbm)
    7d
    A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, C4 Therapeutics, Inc.
    New P1 trial
    |
    Elrexfio (elranatamab-bcmm) • cemsidomide (CFT7455)
    16d
    OPTIMUS-EL: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy (clinicaltrials.gov)
    P2, N=40, Recruiting, Seoul National University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm)
    24d
    ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Massachusetts General Hospital
    New P2 trial
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    1m
    Cytomegalovirus reactivation with severe lymphopenia during elranatamab treatment: a case series in patients with triple-class refractory multiple myeloma. (PubMed, J Infect Chemother)
    All reactivation cases were detected by PCR (>500 IU/mL) and managed pre-emptively with valganciclovir; no CMV disease occurred. Further prospective studies are warranted to optimize infection surveillance and prophylactic strategies in this population. To our knowledge, this is the first case series from Japan to describe infectious complications of ELRA in routine practice, providing important real-world evidence for clinicians.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    Elrexfio (elranatamab-bcmm) • Valcyte (valganciclovir)
    2ms
    MagnetisMM-8: A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Pfizer | Phase classification: P1/2 --> P2
    Phase classification
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    CA057-1040: A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=62, Recruiting, Celgene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm) • mezigdomide (CC-92480)
    2ms
    ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=104, Recruiting, University of Miami | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • dexamethasone • Elrexfio (elranatamab-bcmm)
    3ms
    MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb (clinicaltrials.gov)
    P2, N=187, Active, not recruiting, Pfizer | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Elrexfio (elranatamab-bcmm)
    3ms
    MagnetisMM-9: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (clinicaltrials.gov)
    P2, N=86, Active, not recruiting, Pfizer | Trial completion date: May 2025 --> Oct 2025
    Trial completion date
    |
    Elrexfio (elranatamab-bcmm)
    4ms
    OPTIMUS-EL: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Seoul National University Hospital | Initiation date: May 2025 --> Sep 2025
    Trial initiation date
    |
    Elrexfio (elranatamab-bcmm)
    4ms
    A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (clinicaltrials.gov)
    P1, N=120, Recruiting, Genentech, Inc. | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Elrexfio (elranatamab-bcmm) • Actemra IV (tocilizumab) • cevostamab (RG6160)